Maria Martinez-Chantar

Member of the SAB. Dr Martínez-Chantar, the head of the Liver Disease Lab in CIC bioGUNE and Professor at School of Medicine in Deusto University has been investigating the molecular mechanisms involved in the development of NAFLD and its progression to cirrhosis and liver cancer for the last 20 years. She has a high-level track of record productivity in Nature, Nature Communications, Cell Metabolism, Hepatology and Gastroenterology journals. Since 2005, when she initiated her laboratory as a Principal Investigator her group has been continuously financially supported by government and private funding competitive sources, both national and international like NIH grants and European projects. Dr. Martínez-Chantar is the coordinator of the Translational Area of the National Institute for the study of Liver and Gastrointestinal Diseases (CIBEREHD) and the Scientific Advisory Board of the Molecular Medicine Center C3M in Nice and Health Institute of Valdecilla (IDIVAL). She is also part of the select multinational group “Women in Hepatology” composed only of women, experts in the field of Hepatology, with representatives from Europe and USA. Dr. Martinez-Chantar held collaborations with Pharmaceutical companies AGIOS, Takeda Pharmaceutical and Silence Therapeutics among others and maintained a closed partnership with the company OWL Metabolomics in the development of OWLiver® Care and OWLiver®, two non-invasive assays for fatty liver screening and for NASH diagnosis.